Verition Fund Management’s Neuropace NPCE Stock Holding History

Verition Fund Management’s Portfolio NPCE Stock Details NPCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-20,700	Closed	-$254K	–	3781
2025 Q1	$254K	Buy	+20,700	New	+$259K	﹤0.01%	2937

Other funds holding NPCE

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

KLP

Kent Lake PR Anasco, Puerto Rico $198M AUM 5.21% 1-Year Est. Return

Verition Fund Management's NPCE Position: Q2 2025 in Review

Verition Fund Management sold out of Neuropace (NPCE) in Q2 2025, closing a stake of 20,700 shares — an estimated $254K sold.

Verition Fund Management first reported a position in NPCE in Q1 2025 and held it in 1 quarter. The position peaked at $254K in Q1 2025. 98 funds tracked by Wall St. Rank hold NPCE as of Q2 2025.

Verition Fund Management reported no remaining Neuropace position as of Q2 2025 after selling out during the quarter.
Verition Fund Management sold 20,700 Neuropace shares in Q2 2025, an estimated $254K.
Verition Fund Management first reported a position in Neuropace in Q1 2025 and held it in 1 quarter.
Verition Fund Management's Neuropace position peaked at $254K in Q1 2025.
98 funds tracked by Wall St. Rank held Neuropace as of Q2 2025.

Based on Verition Fund Management's 13F filing for Q2 2025, filed 14 Aug 2025.